A Phase Ib/II Study of the Tolerability, Safety, Efficacy, and Pharmacokinetics of ZG006 in Combination With ZG005 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma(NEC)
Latest Information Update: 01 Jul 2025
At a glance
- Drugs Alveltamig (Primary) ; Nilvanstomig (Primary)
- Indications Neuroendocrine carcinoma; Small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Suzhou Zelgen Biopharmaceuticals
Most Recent Events
- 01 Jul 2025 New trial record